Nivolumab ' s Durable Responses in MMR/MSI Colorectal Cancer Nivolumab ' s Durable Responses in MMR/MSI Colorectal Cancer

Nivolumab as monotherapy or in combination with ipilimumab produced durable clinical responses in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news